Description
The
global next-generation sequencing (NGS) market is anticipated to rise to a
significant valuation by the end of 2021. Next-generation sequencing (NGS) is a
DNA sequencing technology, which has revolutionized genomic research. It has
emerged as an everyday research tool for researchers to study biological
systems rapidly yet precisely. In research laboratories and academic
institutes, the technology is increasingly superseding conventional methods
such as Sanger sequencing. The market is expected to gain remarkable traction
over the forecast period (2017 to 2021) with increasing applications of NGS
Request Free Sample Copy - https://www.radiantinsights.com/research/global-next-generation-sequencing-ngs-market-report-and-forecast-to-2021/request-sample
Launch
of efficient and rapid NSG-based in vitro (IVD) diagnostic products is likely
to augment the market. For instance, in November 2017, Illumina, Inc. announced
the launch of its NextSeq™ 550Dx instrument, a CE-IVD marked and FDA-regulated
NGS system. The instrument includes a research mode and a diagnostic mode,
which renders it possible to develop an array of IVD assays and perform clinical
research on a single platform. It also provides a fully integrated and mounted
analysis software with modular software architecture to facilitate current as
well as future assays.
Development
of novel products and services by key players and their approval by regulatory
bodies such as CE and FDA can provide an upthrust to the market. To put this in
perspective, in the same month, FDA approved IMPACT, the tumor-profiling test
by Memorial Sloan Kettering (MSK) Cancer Center. It is an IVD test that uses next-generation
sequencing to rapidly identify the presence of 468 unique genetic mutations.
The approval of this test will reduce burden on test providers. The test works
by comparing patient’s “normal” sample of tissues or cells to tumor tissues to
detect genetic mutations, which might help in deciding treatment options.
Growing
utilization of advanced platforms for the development of
personalized/customized medicines is estimated to stoke growth of the next
generation sequencing (NSG) market. According to a report available on Radiant
Insights, Inc.; increasing implementation of pre-sequencing protocols can
further stimulate the growth of the market. Rising uptake of the NGS technology
by drug developers and scientists as a tool to gain insights into the genetic
organization of various organisms can propel the market.
North
America is expected to be a key revenue contributor throughout the forecast
period (2017–2021), due to the presence of an advanced HCIT infrastructure.
Some of the key players in the market are CapitalBio Corporation, Thermo Fisher
Scientific, Berry Genomics Co. Ltd., Roche, and Qiagen
View Full Report at- https://www.radiantinsights.com/research/global-next-generation-sequencing-ngs-market-report-and-forecast-to-2021
Radiant
Insights, Inc. offers a plethora of tailor-made and syndicated reports for
various domains, including healthcare, chemicals, medical devices, energy,
materials, and technology. Each report is collated using data from both primary
and secondary types of research
This
report is a total investigation of ebb and flow inclines in the market,
business development drivers, and restrictions. It gives showcase projections
to the coming years. It incorporates investigation of late advancements in
innovation, Doorman's five power demonstrate examination and point by point
profiles of best industry players. The report additionally incorporates a
survey of miniaturized scale and large-scale factors fundamental for the
current market players and new participants alongside nitty gritty esteem chain
examination
About Us
Radiant
Insights is a market research and consulting company offering syndicated
research studies, customized reports, and consulting services. Our market
research studies are designed to facilitate strategic decision making, on the
basis of extensive and in-depth quantitative information, supported by
extensive analysis and industry insights. Using a patented and robust research
methodology, we publish exhaustive research reports covering a host of
industries such as Technology, Chemicals, Materials, and Energy. Radiant
Insights has a strong base of analysts, consultants and domain experts, with
global experience helping us deliver excellence in all research projects we
undertake
Contact Us
Michelle
Thoras
Corporate
Sales Specialist, USA
Radiant
Insights, Inc
201
Spear Street 1100, Suite 3036, San Francisco, CA 94105, United States
Tel:
1-415-349-0054
Toll
Free: 1-888-928-9744
Web: http://www.radiantinsights.com
No comments:
Post a Comment